Theophylline and warfarin interaction studies with grepafloxacin

Clinical Pharmacokinetics

Volumn 33, Issue SUPPL. 1, 1997, Pages 39-46

  Efthymiopoulos, C ^a   Bramer, S L ^a   Maroli, A ^a   Blum, B ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; COUMARIN ANTICOAGULANT; GREPAFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THEOPHYLLINE; WARFARIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE;

EID: 0031453488     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199700331-00008     Document Type: Article

References (21)

1. 1. R Janknegt 1990 Drug interactions with fluoroquinolones J Antimicrob Chemother 6 7 29 10.1093/jac/26.suppl_D.7 Janknegt R. Drug interactions with fluoroquinolones. J Antimicrob Chemother 1990; 6 Suppl. D: 7–29
2. 2. JS Wolfson DC Hooper 1991 Pharmacokinetics of quinolones: newer aspects Eur J Clin Microbiol Infect Dis 10 267 74 1864287 10.1007/BF01967000 1:CAS:528:DyaK3MXlt1KiurY%3D Wolfson JS, Hooper DC. Pharmacokinetics of quinolones: newer aspects. Eur J Clin Microbiol Infect Dis 1991; 10: 267–74
3. 3. JR Brouwers 1992 Drug interactions with quinolone antibacterials Drug Saf 7 268 81 1524699 10.2165/00002018-199207040-00003 1:CAS:528:DyaK38XlsValtb0%3D Brouwers JR. Drug interactions with quinolone antibacterials. Drug Saf 1992; 7: 268–81
4. 4. L Hendeles M Weinberger G Johnson 1978 Monitoring serum theophylline levels Clin Pharmacokinet 9 294 312 10.2165/00003088-197803040-00003 Hendeles L, Weinberger M, Johnson G. Monitoring serum theophylline levels. Clin Pharmacokinet 1978; 9: 294–312
5. 5. K Vance-Bryan DRP Guay JC Rotschafer 1990 Clinical pharmacokinetics of ciprofloxacin Clin Pharmacokinet 19 434 61 2292168 10.2165/00003088-199019060-00003 1:CAS:528:DyaK3MXkt1WgtLc%3D Vance-Bryan K, Guay DRP, Rotschafer JC. Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet 1990; 19: 434–61
6. 6. F Sörgel G Mahr GR Granneman 1992 Effects of 2 quinolone antibacterials, temafloxacin and enoxacin, on theophylline pharmacokinetics Clin Pharmacokinet 22 1 65 74 1319873 10.2165/00003088-199200221-00012 Sörgel F, Mahr G, Granneman GR, et al. Effects of 2 quinolone antibacterials, temafloxacin and enoxacin, on theophylline pharmacokinetics. Clin Pharmacokinet 1992; 22 Suppl. 1: 65–74
7. 7. AE Stuck DK Kim FJ Frey 1992 Fleroxacin clinical pharmacokinetics Clin Pharmacokinet 22 116 31 1551289 10.2165/00003088-199222020-00003 1:STN:280:DyaK383gtVOltg%3D%3D Stuck AE, Kim DK, Frey FJ. Fleroxacin clinical pharmacokinetics. Clin Pharmacokinet 1992; 22: 116–31
8. 8. J Leor S Matatzki 1988 Ofloxacin and warfarin Ann Intern Med 109 761 3190063 1:STN:280:DyaL1M%2FkvVOitw%3D%3D Leor J, Matatzki S. Ofloxacin and warfarin. Ann Intern Med 1988; 109: 761
9. 9. T Linville D Matanin 1989 Norfloxacin and warfarin Ann Intern Med 110 751 2 2930115 1:STN:280:DyaL1M7ptFyqtg%3D%3D Linville T, Matanin D. Norfloxacin and warfarin. Ann Intern Med 1989; 110: 751–2
10. 10. AK Kamada 1990 Possible interaction between ciprofloxacin and warfarin Drug Intell Clin Pharm 24 27 8 1:STN:280:DyaK3c7kt12gsw%3D%3D Kamada AK. Possible interaction between ciprofloxacin and warfarin. Drug Intell Clin Pharm 1990; 24: 27–8
11. 11. WL Nichols EJ Bowie 1993 Standardization of the prothrombin time for monitoring orally administered anticoagulant therapy with use of the International Normalized Ratio system Mayo Clin Proc 68 897 8 8371608 1:STN:280:DyaK3szot1WntQ%3D%3D Nichols WL, Bowie EJ. Standardization of the prothrombin time for monitoring orally administered anticoagulant therapy with use of the International Normalized Ratio system. Mayo Clin Proc 1993; 68: 897–8
12. 12. A Fennerty J Dolben P Thomas 1984 Flexible induction dose regimen for warfarin and prediction of maintenance dose BMJ 288 1268 70 6424820 10.1136/bmj.288.6426.1268 1:STN:280:DyaL2c7nvFyjtA%3D%3D Fennerty A, Dolben J, Thomas P, et al. Flexible induction dose regimen for warfarin and prediction of maintenance dose. BMJ 1984; 288: 1268–70
13. 13. D Miller M Brown 1979 Predicting warfarin and maintenance dosage based on initial response Am J Hosp Pharm 36 1351 5 507078 1:STN:280:DyaL3c%2Fmt1GitA%3D%3D Miller D, Brown M. Predicting warfarin and maintenance dosage based on initial response. Am J Hosp Pharm 1979; 36: 1351–5
14. 14. C Efthymiopoulos SL Bramer A Maroli 1997 Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males Clin Pharmacokinet 33 1 1 8 9433650 10.2165/00003088-199700331-00003 1:CAS:528:DyaK1cXitVKmtg%3D%3D Efthymiopoulos C, Bramer SL, Maroli A. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males. Clin Pharmacokinet 1997; 33 Suppl. 1: 1–8
15. 15. M Gibaldi D Perrier 1982 Pharmacokinetics 2nd Marcel Dekker New York 409 16 Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982; 409–16
16. 16. F Bressolle F Gonçalves A Gouby 1994 Pefloxacin clinical pharmacokinetics Clin Pharmacokinet 27 418 46 7882634 10.2165/00003088-199427060-00003 1:CAS:528:DyaK2MXislOmtb4%3D Bressolle F, Gonçalves F, Gouby A, et al. Pefloxacin clinical pharmacokinetics. Clin Pharmacokinet 1994; 27: 418–46
17. 17. Akiyama H, Odomi M. Report 8850. Metabolism of 14C-OPC-17116 by human cytochrome P450 isoforms expressed by recombinant vaccinia virus
18. 18. C Efthymiopoulos SL Bramer A Maroli 1997 Effect of age and gender on the pharmacokinetics of grepafloxacin Clin Pharmacokinet 33 1 9 17 9433651 10.2165/00003088-199700331-00004 1:CAS:528:DyaK1cXitVKmtw%3D%3D Efthymiopoulos C, Bramer SL, Maroli A. Effect of age and gender on the pharmacokinetics of grepafloxacin. Clin Pharmacokinet 1997; 33 Suppl. 1: 9–17
19. 19. PJ Cook JM Andrews R Wise 1995 Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments J Antimicrob Chemother 35 317 26 7759395 10.1093/jac/35.2.317 1:CAS:528:DyaK2MXktV2qsL4%3D Cook PJ, Andrews JM, Wise R, et al. Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. J Antimicrob Chemother 1995; 35: 317–26
20. 20. KC Lamp EM Bailey MJ Rybak 1992 Ofloxacin clinical pharmacokinetics Clin Pharmacokinet 22 32 6 1559306 10.2165/00003088-199222010-00004 1:STN:280:DyaK383hslamsg%3D%3D Lamp KC, Bailey EM, Rybak MJ. Ofloxacin clinical pharmacokinetics. Clin Pharmacokinet 1992; 22: 32–6
21. 21. S Toon KJ Hopkins FM Garstang 1987 Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects Clin Pharmacol Ther 42 33 41 3474093 10.1038/clpt.1987.104 Toon S, Hopkins KJ, Garstang FM, et al. Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects. Clin Pharmacol Ther 1987; 42: 33–41